RE:RE:RE:RE:RE:RE:RocheYour suggestion Dr Matt has little to do other than sit & wait for the phone is naive, misinformed, childish & upinsulting to the whole program.
should you be following the bouncing ball, majority of Pela trials, while not run directly by Onc, they are " peer reviewed" prior to being published.
Dr Matt is involved in majority of the FDA dealings. He afterall holds the patent rights to Pela.
One coukd say that Anouilh any CEO, however miles from reality.
managing staff, board meeting preparations, public & financial relations etc etc.
i agree Matt has input into the presentation, the physical updating & legal vetting, is the job if I.R person.
on to important things,
we all agree Roche is in with both feet on the Goblett trial.
what we don't know is at what financial level.
now!!,
public relations & getting the word out?
Assuming a N.R. Monday " roshe & Onc to collaborate on pancreatic cancer phase 3 trial"
That would help the SP a lot.
since we know that, obviously the SP is way way underpriced.
So , why not shout from the top of the hill!
Obviously more to come....no use sending out 1/2 of a NR thiis week, only to say ,we're not sure of details .
read between the lines & appreciate the information. Shareprice is beyond silly low.